| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, University of Toronto, and the Division of Endocrinology and Metabolism, St. Michael’s Hospital (T.M.M., L.G.R.), Toronto, Ontario, Canada M5B 1A6; and the Endocrine Unit (P.D., F.R.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114
Correspondence: Address all correspondence and requests for reprints to: Timothy M. Murray, M.D., F.R.C.P.(C), St. Michael’s Hospital, 38 Shuter Street, Suite 213, Toronto, Ontario M5B 1A6, Canada. E-mail: drtimothy.murray{at}utoronto.ca
PTH is a major systemic regulator of the concentrations of calcium, phosphate, and active vitamin D metabolites in blood and of cellular activity in bone. Intermittently administered PTH and amino-terminal PTH peptide fragments or analogs also augment bone mass and currently are being introduced into clinical practice as therapies for osteoporosis. The amino-terminal region of PTH is known to be both necessary and sufficient for full activity at PTH/PTHrP receptors (PTH1Rs), which mediate the classical biological actions of the hormone. It is well known that multiple carboxyl-terminal fragments of PTH are present in blood, where they comprise the major form(s) of circulating hormone, but these fragments have long been regarded as inert by-products of PTH metabolism because they neither bind to nor activate PTH1Rs. New in vitro and in vivo evidence, together with older observations extending over the past 20 yr, now points strongly to the existence of novel large carboxyl-terminal PTH fragments in blood and to receptors for these fragments that appear to mediate unique biological actions in bone. This review traces the development of this field in the context of the evolution of our understanding of the "classical" receptor for amino-terminal PTH and the now convincing evidence for these receptors for carboxyl-terminal PTH. The review summarizes current knowledge of the structure, secretion, and metabolism of PTH and its circulating fragments, details available information concerning the pharmacology and actions of carboxyl-terminal PTH receptors, and frames their likely biological and clinical significance. It seems likely that physiological parathyroid regulation of calcium and bone metabolism may involve receptors for circulating carboxy-terminal PTH ligands as well as the action of amino-terminal determinants within the PTH molecule on the classical PTH1R.
This article has been cited by other articles:
 |
|
 |
|
  A. A. Pioszak, N. R. Parker, T. J. Gardella, and H. E. Xu Structural Basis for Parathyroid Hormone-related Protein Binding to the Parathyroid Hormone Receptor and Design of Conformation-selective Peptides J. Biol. Chem., October 9, 2009; 284(41): 28382 - 28391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Drechsler, V. Krane, D. C Grootendorst, E. Ritz, K. Winkler, W. Marz, F. Dekker, C. Wanner, and for the German Diabetes and Dialysis Study Investi The association between parathyroid hormone and mortality in dialysis patients is modified by wasting Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3151 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rao, D. Ansell, J. A. Gilg, S. J. Davies, E. J. Lamb, and C. R. V. Tomson Effect of change in renal replacement therapy modality on laboratory variables: a cohort study from the UK Renal Registry Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2877 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Zhang, J. A. Frangos, and M. Chachisvilis Mechanical stimulus alters conformation of type 1 parathyroid hormone receptor in bone cells Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1391 - C1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wan, C. Yang, J. Li, X. Wu, H. Yuan, H. Ma, X. He, S. Nie, C. Chang, and X. Cao Parathyroid hormone signaling through low-density lipoprotein-related protein 6 Genes & Dev., November 1, 2008; 22(21): 2968 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.M. Au, K. McDonald, A. Gill, M. Sywak, T. Diamond, A. D. Conigrave, and R. J. Clifton-Bligh PTH Mutation with Primary Hyperparathyroidism and Undetectable Intact PTH N. Engl. J. Med., September 11, 2008; 359(11): 1184 - 1186. [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Miedlich and A. B. Abou-Samra Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E665 - E671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Pioszak and H. E. Xu Molecular recognition of parathyroid hormone by its G protein-coupled receptor PNAS, April 1, 2008; 105(13): 5034 - 5039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sneve, N. Emaus, R. M. Joakimsen, and R. Jorde The association between serum parathyroid hormone and bone mineral density, and the impact of smoking: the Tromso Study Eur. J. Endocrinol., March 1, 2008; 158(3): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al. Bone disease after renal transplantation Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Barnes, S. Kakar, S. Vora, E. F. Morgan, L. C. Gerstenfeld, and T. A. Einhorn Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone Treatment J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, H. Liu, L. Qin, J. Tamasi, M. Bergenstock, S. Shapses, J. H. M. Feyen, D. A. Notterman, and N. C. Partridge Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis J. Biol. Chem., November 9, 2007; 282(45): 33086 - 33097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ono, K. Nakashima, E. Schipani, T. Hayata, Y. Ezura, K. Soma, H. M. Kronenberg, and M. Noda Constitutively Active Parathyroid Hormone Receptor Signaling in Cells in Osteoblastic Lineage Suppresses Mechanical Unloading-induced Bone Resorption J. Biol. Chem., August 31, 2007; 282(35): 25509 - 25516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Canalis, A. Giustina, and J. P. Bilezikian Mechanisms of Anabolic Therapies for Osteoporosis N. Engl. J. Med., August 30, 2007; 357(9): 905 - 916. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jolette, C. E. Wilker, S. Y. Smith, N. Doyle, J. F. Hardisty, A. J. Metcalfe, T. B. Marriott, J. Fox, and D. S. Wells Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats Toxicol Pathol, December 1, 2006; 34(7): 929 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Berruti, M Tucci, D Generali, A Mosca, M Ardine, F Vana, and L Dogliotti Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation Ann. Onc., December 1, 2006; 17(12): 1854 - 1855. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cranney, A. Papaioannou, N. Zytaruk, D. Hanley, J. Adachi, D. Goltzman, T. Murray, A. Hodsman, and for the Clinical Guidelines Committee of Osteoporo Parathyroid hormone for the treatment of osteoporosis: a systematic review. Can. Med. Assoc. J., July 4, 2006; 175(1): 52 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Selim, M. Mahon, H. Juppner, F. R. Bringhurst, and P. Divieti Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling Am J Physiol Cell Physiol, July 1, 2006; 291(1): C114 - C121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huan, K. Olgaard, L. B. Nielsen, and E. Lewin Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Friedman and W. G. Goodman PTH(1-84)/PTH(7-84): a balance of power Am J Physiol Renal Physiol, May 1, 2006; 290(5): F975 - F984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Divieti, A. I. Geller, G. Suliman, H. Juppner, and F. R. Bringhurst Receptors Specific for the Carboxyl-Terminal Region of Parathyroid Hormone on Bone-Derived Cells: Determinants of Ligand Binding and Bioactivity Endocrinology, April 1, 2005; 146(4): 1863 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Seeman and G. J. Strewler Clinical and Basic Research Papers - January 2005 Selections IBMS BoneKEy, February 1, 2005; 2(2): 1 - 6. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
